About this Webinar
Join Nancy Jaser, Analyst in Infectious Diseases, for insight into why the respiratory syncytial virus (RSV) prophylaxis market is expected to skyrocket from $454.8m in 2020 to $6.3bn by 2030 across the eight major markets (8MM).
The webinar will last approximately 60 minutes and will delve into:
What are the most promising late-stage pipeline products for RSV prophylaxis?
How do the clinical and commercial attributes of late-stage pipeline products compare with one another, and against existing RSV prevention options?
What are the remaining unmet needs in RSV prophylaxis?
What drivers and barriers will affect RSV prophylaxis sales in the 8MM over the forecast period?
Speakers
Nancy Jaser
Nancy Jaser, PharmD/MBA, is an analyst on the Infectious Diseases team at GlobalData in New York. Nancy’s primary role is coverage of rare and infectious diseases, with an emphasis on SARS-CoV-2, respiratory syncytial virus (RSV), and sickle cell disease. Nancy holds an MBA from Rutgers Business School and a Doctor of Pharmacy from the University of Connecticut. She has extensive experience in biotechnology equity research, pharmaceutical consulting, and clinical pharmacy. Prior to joining the Infectious Diseases team, Nancy served as an editorial analyst at GlobalData where she supported the investigative journalism team for research and analysis of pressing biopharmaceutical catalysts.
Past Webinars
View more past webinarsUpcoming Webinars
View more upcoming webinarsSearch companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer


